Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, M. Metz, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini, E. Şavk, G. Sussman, R. Szalewski, I.W. Herniczek, H. Windom, B.Yang, S. Haemmerle, K. Lheritier, P.G.P. Machado, El-D. Martzloff, N. Seko, P. Wang, M. Maurer, A. Zharkov

Please click HERE to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this LINK to access the publication once it has been presented at the congress

GUF 2024, The Global Urticaria Forum. (GUF) , 4—5 December 2024